Company
Description
Founded in 2022 by Bain Capital, Tenacia is a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders.
Our seasoned management team brings decades of drug development experience from both MNCs and biotechs. Their deep understanding of complex disease biology and insights into unmet patient needs have empowered us to create a highly efficient neuroscience R&D platform with a proven track record of advancing novel therapies.
Focused on neuroscience, we started with clinically de-risked products and rapidly built a diverse, differentiated pipeline for clinical and commercial advancement. By leveraging internal expertise and strategic collaborations, we strive to translate cutting-edge neuroscience into life-changing therapies for patients with debilitating neurological disorders.
Empowered by our founder and strategic investor, Bain Capital – through its significant initial investment, long-term commitment and extensive life science network – Tenacia is poised to become a leading neuroscience company in China and deliver substantial value to our shareholders while upholding an unwavering commitment to the patients.
